547 related articles for article (PubMed ID: 9812178)
1. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Hsu A; Granneman GR; Bertz RJ
Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract][Full Text] [Related]
4. Saquinavir. Clinical pharmacology and efficacy.
Vella S; Floridia M
Clin Pharmacokinet; 1998 Mar; 34(3):189-201. PubMed ID: 9533981
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.
Koudriakova T; Iatsimirskaia E; Utkin I; Gangl E; Vouros P; Storozhuk E; Orza D; Marinina J; Gerber N
Drug Metab Dispos; 1998 Jun; 26(6):552-61. PubMed ID: 9616191
[TBL] [Abstract][Full Text] [Related]
6. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
Hsu A; Granneman GR; Cao G; Carothers L; Japour A; El-Shourbagy T; Dennis S; Berg J; Erdman K; Leonard JM; Sun E
Antimicrob Agents Chemother; 1998 Nov; 42(11):2784-91. PubMed ID: 9797204
[TBL] [Abstract][Full Text] [Related]
8. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
9. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of darunavir.
Rittweger M; Arastéh K
Clin Pharmacokinet; 2007; 46(9):739-56. PubMed ID: 17713972
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
15. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry M; Mulcahy F; Merry C; Gibbons S; Back D
Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Kempf DJ; Marsh KC; Kumar G; Rodrigues AD; Denissen JF; McDonald E; Kukulka MJ; Hsu A; Granneman GR; Baroldi PA; Sun E; Pizzuti D; Plattner JJ; Norbeck DW; Leonard JM
Antimicrob Agents Chemother; 1997 Mar; 41(3):654-60. PubMed ID: 9056009
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
Kaeser B; Zandt H; Bour F; Zwanziger E; Schmitt C; Zhang X
Antimicrob Agents Chemother; 2009 Feb; 53(2):609-14. PubMed ID: 19015329
[TBL] [Abstract][Full Text] [Related]
19. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]